Dr Reddy's Laboratories on Wednesday reported an unexpected loss for the latest quarter after incurring write-off related losses at its German unit and trimmed revenue growth forecast for this fiscal year.

Takeda Pharmaceutical, Japan's largest drugmaker, may look for acquisitions in India to boost its presence in Asia's third-largest economy, the Financial Express reported on Wednesday.

Dr Reddy's Laboratories has filed for marketing a generic version of Pfizer's cholesterol-lowering drug Lipitor in the U.S., the company said on Saturday.

India will resolve a dispute with the European Union over generic drugs in an amicable way, Trade Minister Anand Sharma said on Friday.

Drug maker Dr Reddy's Laboratories Ltd said on Friday quarterly profits doubled from a year ago helped by the launch of new generics abroad, beating forecast and sending its shares higher.

Western drugmakers are stepping up the hunt for emerging market "tigers" in India.

Global conglomerate General Electric Co. (GE) is making a major push in developing its healthcare business by integrating all its India business within Wipro GE Healthcare, a joint venture (JV) set up by the two companies in 1990.

India's growing pharmaceutical industry is expected to touch $20 billion by 2015 and feature among the global top 10, a joint report published by the Federation of Indian Chambers of Commerce and Industry (FICCI) and Ernst & Young said.

Shares of India's second largest generic drug maker Dr. Reddy's Laboratories Ltd (Dr. Reddy's) fell 1.45 percent at the Bombay Stock Exchange on Friday to close down at Rs.809.25 after its promoters scoffed rumors that they were keen on selling stake in the company to raise funds.

U.S. private equity firm Blackstone is in talks to buy a 63 percent stake in an Indian agro-chemicals and veterinary drugs maker for about 6.3 billion rupees ($130 million), the Economic Times reported on Thursday, citing an unnamed person with knowledge of the matter.

In what is being billed as a win-win deal, India's leading chain of private hospitals Fortis Healthcare Ltd has agreed to buy 10 hospitals from Wockhardt Hospitals Ltd for a consideration of Rs.909 crore.

Glenmark Pharmaceuticals saw its shares plunge 3.92 percent to end lower at Rs.214.45 at the Bombay Stock Exchange on Thursday after news spread that a drug the pharma major was developing together with US partner Forest Laboratories to treat smoker's cough had failed in a mid-stage trial.

Hospital chain Fortis Healthcare Ltd expects to launch a 10-billion-rupee rights issue in July, its finance chief said on Tuesday.

Fortis Healthcare Ltd said on Thursday it has assumed charge of S.L. Raheja Hospital in Mumbai, taking over the operations and management with immediate effect, widening its presence in western India.

Swiss drugmaker Novartis AG is upping an offer to increase its stake in its India unit to $111 million or 450 rupees ($15.9) per share, from a previous 351 rupees, it said on Thursday.

Malvinder Mohan Singh, CEO and managing director of India's biggest drug manufacturer Ranbaxy Laboratories, said he was not forced to step down, ending market speculation that he was made to resign for failing to curb the drug firm's growing losses.

Malvinder Mohan Singh, CEO and managing director of India's biggest generic drug manufacturer Ranbaxy Laboratories, has resigned on Sunday, following a reconstitution of its top management body.

India's top generic drug maker Ranbaxy Laboratories Ltd said it has acquired trademarks, product dossiers and marketing rights from Ochoa Laboratories Ltd (Ochoa) for its entire range of dermatological and lifestyle products.

India's leading drug maker Dr. Reddy's Laboratories has posted a net loss of Rs.977.7 crore in net profit for the quarter ended March 31, 2009, attributing it to a one-time impairment charge of Rs.1402.3 crore taken on its German unit Betapharm.